Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial-Reference-Cited by-同舟云学术

Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial

Published:2022-07 Issue:10348 Volume:400 Page:273-282
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Reich Kristian,Thyssen Jacob P,Blauvelt Andrew,Eyerich Kilian,Soong Weily,Rice Zakiya P,Hong H Chih-ho,Katoh Norito,Valenzuela Fernando,DiBonaventura Marco,Bratt Tamara A,Zhang Fan,Clibborn Claire,Rojo Ricardo,Valdez Hernan,Kerkmann Urs

Funder

Pfizer

Publisher

Elsevier BV

Subject

General Medicine

Reference18 articles.

1. Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape;Boguniewicz;Ann Allergy Asthma Immunol,2018

2. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease;Bieber;Nat Rev Drug Discov,2022

3. Factors associated with patient-reported importance of skin clearance among adults with psoriasis and atopic dermatitis;Egeberg;J Am Acad Dermatol,2019

4. Quantifying patient preferences for systemic atopic dermatitis treatments using a discrete-choice experiment;Boeri;J Dermatolog Treat,2020

5. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study;Silverberg;Ann Allergy Asthma Immunol,2018

Cited by 117 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Short- and long-term cost-effectiveness of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis in China;Journal of Medical Economics;2024-09-13

2. JAK inhibitor selectivity: new opportunities, better drugs?;Nature Reviews Rheumatology;2024-09-09

3. EXPERIENCE OF ABROCITINIB IN ATOPIC DERMATITIS;Russian Journal of Skin and Venereal Diseases;2024-09-08

4. Off-Label Uses of Abrocitinib: Review of Emerging Therapeutic Applications beyond Atopic Dermatitis;Life;2024-09-06

5. Outcomes of systemic Janus kinase inhibitors following prior dupilumab use for atopic dermatitis: An evidence-based review;JAAD International;2024-09